Stockscreener 앱 받기
9.68
2.33%
0.22
시간 외 거래:
9.68
전일 마감가:
$9.46
열려 있는:
$9.3
하루 거래량:
994.22K
Relative Volume:
1.10
시가총액:
$512.61M
수익:
-
순이익/손실:
$-23.56M
주가수익비율:
-12.31
EPS:
-0.7861
순현금흐름:
$-15.45M
1주 성능:
-4.25%
1개월 성능:
+23.94%
6개월 성능:
+342.01%
1년 성능:
+396.41%
1일 변동 폭
$9.01
$10.09
1주일 범위
$9.01
$11.61
52주 변동 폭
$1.34
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
9.68 | 500.96M | 0 | -23.56M | -15.45M | -0.7861 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2026-02-09 | 개시 | Mizuho | Outperform |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma (NASDAQ:IMMX) Shares Down 8.9%Should You Sell? - MarketBeat
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3%What's Next? - MarketBeat
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Drops By 13.4% - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Hits New 12-Month HighHere's Why - MarketBeat
Immix Biopharma (IMMX) to Release Earnings on Monday - MarketBeat
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch - MSN
Immix Biopharma (NASDAQ:IMMX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $15.00 - Defense World
IMMX Technical Analysis & ETF Price Forecast - Intellectia AI
Immix Biopharma (NASDAQ:IMMX) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Citizens initiates Immix Biopharma stock coverage with outperform rating By Investing.com - Investing.com Canada
Citizens initiates Immix Biopharma stock coverage with outperform rating - Investing.com South Africa
Aug Wrap: Does Immix Biopharma Inc have consistent dividend growthMarket Growth Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Macro Review: Is Immix Biopharma Inc stock a good pick for beginners2026 Market Overview & Growth Focused Entry Point Reports - baoquankhu1.vn
Why Immix Biopharma Inc. stock could rally in 20262026 Big Picture & Reliable Trade Execution Plans - Naître et grandir
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
33,035,515 Common Stock of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 8-MAR-2026. - marketscreener.com
Is Immix Biopharma Inc. stock a top momentum play2025 Big Picture & Detailed Earnings Play Strategies - Naître et grandir
Trade Recap: Is Immix Biopharma Inc in a bullish channel2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Insider Buy: What dividend growth rate does Immix Biopharma Inc offerTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
IMMX Should I Buy - Intellectia AI
IMMX Technical Analysis & Stock Price Forecast - Intellectia AI
IMMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment manager Saturn V holds 6.97% of Immix Biopharma (IMMX) - Stock Titan
Immix Biopharma (IMMX) sees Janus Henderson report 7.4% stake - Stock Titan
Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Yahoo Finance
Immix Biopharma (NASDAQ:IMMX) Now Covered by Mizuho - MarketBeat
Mizuho Initiates Immix Biopharma at Outperform With $14 Price Target - marketscreener.com
Mizuho initiates coverage of Immix Biopharma (IMMX) with outperform recommendation - MSN
Immix Biopharma (NASDAQ:IMMX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Stock Recap: Whats the MACD signal for Immix Biopharma IncJuly 2025 Selloffs & Safe Entry Point Alerts - baoquankhu1.vn
Is Immix Biopharma Inc. stock a good pick for beginnersJuly 2025 Volume & High Accuracy Investment Entry Signals - mfd.ru
FDA grants breakthrough therapy status to ImmixBio’s amyloidosis drug By Investing.com - Investing.com Canada
Immix Biopharma stock climbs after FDA grants breakthrough therapy status By Investing.com - Investing.com Canada
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - GlobeNewswire
FDA grants Breakthrough status to NXC-201 in AL amyloidosis with no approved drugs - Stock Titan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Market Recap: Why Immix Biopharma Inc. stock remains undervaluedQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Is Immix Biopharma Inc stock a good pick for beginnersMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Published on: 2026-01-13 06:33:30 - Улправда
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga
Immix Biopharma (NASDAQ:IMMX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Immix Biopharma to offer and sell up to $750 million in securitiesSEC filing - marketscreener.com
Immix Biopharma — NXC-201’s path to BLA submission - Smartkarma
Why analysts upgrade Immix Biopharma Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - ulpravda.ru
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immix Biopharma Inc 주식 (IMMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
1.20%
0.06%
자본화:
|
볼륨(24시간):